Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer

Prostate cancer is the most common noncutaneous malignancy affecting men in North America. Radical prostatectomy remains a definitive treatment for prostate cancer. However, prostate surgeries are still performed “blindly” with the extent of tumor infiltration past the margins of the surgery only being determined postoperatively. An imaging modality that can be used during surgery is needed to help define the tumor margins. With its abundant expression in prostate cancer, prostate-specific membrane antigen (PSMA) is an ideal target for detection of prostate cancer. The purpose of this study was to develop PSMA-targeted near-infrared (NIR) optical imaging probes for intraoperative visualization of prostate cancer. We synthesized a high-affinity PSMA ligand (PSMA-1) with low molecular weight and further labeled it with commercially available NIR dyes IRDy800 and Cy5.5. PSMA-1 and PSMA-1–NIR conjugates had binding affinities better than the parent ligand Cys-CO-Glu. Selective binding was measured for each of the probes in both in vitro and in vivo studies using competitive binding and uptake studies. Interestingly, the results indicated that the pharmacokinetics of the probes was dependent of the fluorophore conjugated to the PSMA-1 ligand and varied widely. These data suggest that PSMA-targeted probes have the potential to be further developed as contrast agents for clinical intraoperative fluorescence-guided surgery. Mol Cancer Ther; 13(11); 2595–606. ©2014 AACR.

[1]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[2]  W. Eckelman,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[3]  G. Murphy,et al.  Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356) , 1991, The Prostate.

[4]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[5]  F. Jolesz,et al.  Multimodality intraoperative MRI for brain tumor surgery , 2010, Expert review of neurotherapeutics.

[6]  Stanley J. Goldsmith,et al.  Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[7]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  S. Horenblas,et al.  Intraoperative radioguidance with a portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Rolf Hilgenfeld,et al.  Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. , 2007, Acta crystallographica. Section D, Biological crystallography.

[10]  Serge K. Lyashchenko,et al.  A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. , 2014, The Journal of urology.

[11]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[12]  J. Seidel,et al.  N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer , 2008, Clinical Cancer Research.

[13]  M. Sadelain,et al.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? , 2001, Critical reviews in immunology.

[14]  Martin G Pomper,et al.  Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. , 2012, Bioconjugate chemistry.

[15]  Martin G Pomper,et al.  A low molecular weight PSMA-based fluorescent imaging agent for cancer. , 2009, Biochemical and biophysical research communications.

[16]  N. Bander.  Technology Insight: monoclonal antibody imaging of prostate cancer , 2006, Nature Clinical Practice Urology.

[17]  Jean-Alexandre Long,et al.  Robotic retroperitoneal transvaginal natural orifice translumenal endoscopic surgery (NOTES) nephrectomy: feasibility study in a cadaver model. , 2013, Urology.

[18]  Martin G Pomper,et al.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.

[19]  M. Wirth,et al.  Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy , 1995, The Prostate.

[20]  G. Swanson,et al.  Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment. , 2013, Urologic oncology.

[21]  J. Richie,et al.  Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Hisataka Kobayashi,et al.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. , 2011, Bioconjugate chemistry.

[23]  William C. Eckelman,et al.  First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[24]  W. Ellis,et al.  Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. , 2010, The Journal of urology.

[25]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[26]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[27]  F Sánchez,et al.  Performance tests of two portable mini gamma cameras for medical applications. , 2006, Medical physics.

[28]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[29]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[30]  M M Haglund,et al.  Enhanced optical imaging of human gliomas and tumor margins. , 1996, Neurosurgery.

[31]  Z. Lee,et al.  Structure-Activity Relationships of 2′,5′-Oligoadenylate Analogue Modifications of Prostate-Specific Membrane Antigen (PSMA) Antagonists , 2012, Nucleosides, nucleotides & nucleic acids.

[32]  F. Difilippo,et al.  Improving the biodistribution of PSMA‐targeting tracers with a highly negatively charged linker , 2014, The Prostate.

[33]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[34]  Zhenghong Lee,et al.  Targeted treatment of prostate cancer , 2007, Journal of cellular biochemistry.

[35]  M M Haglund,et al.  Enhanced optical imaging of rat gliomas and tumor margins. , 1994, Neurosurgery.

[36]  M. Pomper,et al.  Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer , 2005, Clinical Cancer Research.

[37]  Takashi Tsukamoto,et al.  High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen , 2005, Molecular imaging.

[38]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Martin G Pomper,et al.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. , 2009, Cancer research.

[40]  W. Eckelman,et al.  123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy , 2011, The Journal of Nuclear Medicine.

[41]  Alexander D. MacKerell,et al.  A Small Molecule Agonist of EphA2 Receptor Tyrosine Kinase Inhibits Tumor Cell Migration In Vitro and Prostate Cancer Metastasis In Vivo , 2012, PloS one.

[42]  J. Bowie,et al.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. , 2003, Molecular biology of the cell.

[43]  Philip S Low,et al.  Development of tumor-targeted near infrared probes for fluorescence guided surgery. , 2013, Bioconjugate chemistry.

[44]  A. Deblasio,et al.  Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. , 1994, Cancer research.

[45]  Tiancheng Liu,et al.  A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. , 2010, Bioorganic & medicinal chemistry letters.

[46]  J. Konvalinka,et al.  Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III , 2009, The FEBS journal.

[47]  Martin G Pomper,et al.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. , 2010, Journal of medicinal chemistry.

[48]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Pomper,et al.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. , 2008, Journal of medicinal chemistry.

[50]  S. Vallabhajosula,et al.  Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. , 2003, The Journal of urology.

[51]  R. Silverman,et al.  2-5A Ligands—A New Concept for the Treatment of Prostate Cancer , 2007, Nucleosides, nucleotides & nucleic acids.